Background: Repetitive Transcranial Magnetic Stimulation (rTMS) is commonly ad-
| INTRODUC TI ON
Repetitive Transcranial Magnetic Stimulation (rTMS) has gained increasingly widespread clinical use for treatment of Major Depressive Disorder (MDD) since it was approved in the US in 2008 for treatment of antidepressant drug-resistant unipolar major depression. Although initial trials examined the efficacy of rTMS monotherapy for MDD (George et al., 2010; Levkovitz et al., 2015; O'Reardon et al., 2007) , in clinical practice physicians typically administer rTMS as an augmentation therapy, rather than discontinue a patient's current medications. Several studies have confirmed the clinical effectiveness of rTMS in patients who are taking adjunctive antidepressants (Carpenter et al., 2012; George, Taylor, & Short, 2013) or have examined the effects of initiating rTMS for a brief period at the outset of treatment with antidepressant medication as a means of bolstering medication response (Berlim, den Eynde Van, & Daskalakis, 2013) . However, none have examined the effects of different classes of medication on rTMS treatment outcome.
Clinical guidelines presently address concomitant medication use solely from a safety perspective. Caution is advised when administering rTMS to patients who are taking stimulants or other medications that may lower seizure threshold, or following a decrease or discontinuation of antiepileptics, benzodiazepines, or other medications with anticonvulsant properties (McClintock et al., 2018) .
A recent consensus states that "TMS therapy can be administered in the presence or absence of concurrent antidepressant or other psychotropic medications" (Perera et al., 2016) . Although there are no reports of rTMS clinical outcomes in relationship to concurrent medications, experimental pharmaco-TMS-EEG studies in singleor paired-pulse paradigms have routinely demonstrated effects of central nervous system drugs on measures of cortical excitability, connectivity, and plasticity (Ziemann, 2004) . Given that therapeutic effects of rTMS are posited to result from long-term potentiation (LTP) or long-term depression (LTD)-like effects in critical brain circuits (Kobayashi et al., 2017; Ziemann et al., 2015) , it is reasonable to hypothesize that concurrent psychotropic medications could influence clinical outcome.
The present study explored associations between concomitant medications and rTMS outcome during treatment of MDD.
The motivation for this investigation was twofold: first, to examine evidence that could help inform clinical decision-making when addressing the integration of psychopharmacology with rTMS; and second, to identify those medication mechanisms of action (MOAs) that might help elucidate which classes of psychotropic drugs are most likely to interact with rTMS effects. We therefore examined the effect of standard medication classes on treatment outcome in 181 patients receiving a standard clinical course of rTMS. In supplementary analyses (Data S1), we also examined the effects of medication on outcome using a novel MOA-based schema based on the neurochemical actions of individual drugs.
Results identified categories of medication use that were associated with greater or lesser clinical improvement over the course of rTMS.
| ME THOD

| Overview and subjects
This retrospective chart study was undertaken to examine potential relationships between categories of medication use and clinical outcome to rTMS treatment for depression. There were no experimental manipulations; rTMS treatment and medication data collection were performed naturalistically.
Subjects (n = 227) were all patients treated in the TMS UCLA
Clinical and Research Program between September 2009 and
January 2017 and who provided written informed consent to participate in this UCLA IRB-approved study. Subjects were treated in accordance with the 2013 Declaration of Helsinki. Analyses included subjects who had baseline medication data available, received at least 10 rTMS treatment sessions for non-psychotic MDD, and were assessed at baseline using the 30-item Inventory of Depressive Symptomatology Self Report (IDS-SR30) (Rush, Gullion, Basco, Jarrett, & Trivedi, 1996) . Figure 1 shows a data flow diagram of the analyzable sample (n = 181).
| Medication categories
Medications were classified according to drug classes (Table 1) and "Other." The "Other" medication class was heterogeneous and included opiates, thyroid, melatonin, and memantine. These medications do not have clear effects on cortical excitability or plasticity, and excepting thyroid hormone, they lack established antidepressant augmentation efficacy. Only seven subjects were taking thyroid hormone at study entry. An alternate classification schema also examined outcome in relation to use of medications grouped into eight non-exclusive categories that reflected a multiplicity of neurochemical MOAs (Roth, Sheffler, & Kroeze, 2004) . These are presented in Data S1. Adherence to medications was confirmed by patient report and verified by collateral history from their prescribing physicians.
| Subjects' medication coding
Medication information for each subject was obtained from electronic records that listed all medications at the beginning of treatment. Subject data were coded in a binary "yes/no" fashion for each category. For example, a subject taking only venlafaxine, would have been coded as "1" under the standard category "SNRI." For medications having dose-dependent effects, each subject was coded as warranted by the dose. For example, the following medications were considered largely sub-therapeutic and therefore lacking significant effects at their primary targets, at the following daily doses: trazodone (below 100 mg); quetiapine (below 100 mg); venlafaxine (below 100 mg); mirtazapine (below 15 mg). For psychotropic medications used on an as-needed (prn) basis, we estimated the average daily dose by patient report and then used our standard criteria. For those rare patients who started or stopped a medication during the course of rTMS (approximately 5%), we included them in that category as a conservative measure. For each subject, we computed "Total number of medications," to serve as general measure of overall medication use or burden.
| rTMS treatment
Subjects were treated using the NeuroStar TMS System (Neuronetics, Inc, Malvern, PA) with 30 sessions scheduled over (McDonald et al., 2011) . Within these options, up to 5,000 total pulses were delivered per session. Treatment adjustments were guided by changes in symptom severity, and physician clinical judgment, within established treatment guidelines utilizing a "measurement-based care" approach (Guo et al., 2015) .
| Data analysis
Medication categories that were in use by at least 20% of the sample were examined in association with clinical outcomes. This strategy reduced the number of tests and ensured meaningfully sized analysis samples. Change in the IDS-SR30 total score from baseline to week
TA B L E 1 Medications categorized by standard classes
Standard category
Medication name
Fluoxetine ( 2, and change in the IDS-SR30 total score across weeks 2, 4, and 6, were examined as co-primary outcomes, using linear regression and linear mixed model analysis, respectively. Analyses were performed using SPSS version 24; because this was an exploratory, hypothesis-generating investigation, we reported all findings meeting a significance threshold of p ≤ 0.05 without correction for multiple comparisons.
The week 2 outcome was of specific interest because the first 2 weeks were the most homogeneous with respect to treatment parameters including intensity (100%-120% MT), "dose" (~3,000 pulses), frequency (10 Hz), and site (i.e., left DLPFC). Separate linear regression analyses were performed to examine each medication category as a dichotomous predictor of raw change in the IDS-SR30 total score at week 2, in models that included the baseline IDS-SR30 total score as a covariate. Medication categories that were identified as significant predictors after controlling for overall baseline severity were then evaluated in further models that examined baseline IDS-SR30 anxiety and non-anxiety item totals as separate covariates, and examined covariates of age and other clinical characteristics (i.e., total number of medications) that differed between users and non-users of a given medication category. Baseline anxiety was assessed using an 8-item subscale 23, 24, 25, 26, 27, 28, 30) (Wardenaar et al., 2010) .
In statistical models that examined baseline anxiety as a covariate, IDS-SR30 item totals were parsed into an anxiety subscale, and a non-anxiety subscale in order to avoid collinearity between the subscale and the total score.
Linear mixed model analyses were used to assess relationships between each medication category and change in IDS-SR30 total score over 6 weeks of treatment. This approach was used to examine associations between medication use and response to clinical rTMS more generally, that is, as a treatment modality, allowing for variability and flexible changes in specific parameters. We compared symptom severity changes between users versus non-users of each medication category in separate linear mixed model analyses conducted using restricted maximum likelihood (REML). Changes in IDS-SR30 total score at weeks 2, 4, and 6 were calculated from baseline, yielding a within-group factor of time with three levels.
Mixed models examined change over time, co-varying for baseline IDS-SR30. Other covariates were examined as dictated by the specific medication category.
| RE SULTS
| Clinical, demographic, and medication use characteristics of the sample
The analyzable sample (n = 181) included 98 females and 83 males with a mean age of 46.6 ± 16.6 years entering treatment with a mean IDS-SR30 total score of 42.8 ± 11.1, and an anxiety subscale score of 9.7 ± 4.3. Overall, 92% of subjects were taking at least one psychotropic medication; 78% were taking at least one antidepressant. Among medication users, the mean number of medications was 4.2 ± 2.4, including 1.3 ± 0.8 antidepressants. Table 2 shows medication use by category. Seven of twelve clinically-based medication categories were in use by 20% or more of the sample.
| Clinical outcomes in the overall sample
Subjects showed a mean decrease (improvement) of 7.9 ± 9.8 points 
| Medication categories and week 2 outcome
Regression models for each medication category, controlling for baseline IDS-SR30, found significant effects for BDZs (p = 0.02) and psychostimulants (p = 0.05) (Table 3a) . BDZ use was associated with less improvement at week 2, whereas psychostimulant use was associated with greater improvement. These medication effects remained significant after adding covariates of age, baseline anxiety, and total number of medications (Table 3b ). Age was examined as a covariate because it had been significantly associated with week 2 outcome, and anxiety because it is often associated with BDZ use. Furthermore, baseline anxiety was greater in psychostimulant users versus non-users (10.8 ± 4.4 vs.
9.2 ± 4.1, p = 0.02). Total number of medications used was greater in psychostimulant users versus non-users (4.8 ± 2.4 vs. 3.4 ± 2.6; p < 0.001).
| Medication categories and changes in symptom severity over weeks 2, 4, 6
Psychostimulant use was significantly associated with greater improvement over the course of treatment including baseline IDS-SR30 as a covariate (F (1, 176.744) = 4.94, p = 0.03) ( Table 4) . Estimated marginal means were −13.09 for subjects who were taking a psychostimulant versus −9.56 for those who were not. Total number of medications and anxiety subscale variables were not significant in any of the mixed models and so were excluded from final models.
The interaction between time and medication category was not significant in any of the models. Figure 2 shows IDS-SR30 changes for benzodiazepine and psychostimulant users and non-users at weeks 2, 4, and 6.
TA B L E 3 Results of linear regression analyses examining medication categories as predictors of week 2 outcome of rTMS for depression:
(a) Models with baseline IDS-SR30 total score covariate only; (b) Significant models with baseline anxiety and non-anxiety item total covariates, and additional covariates 
| Medication categories in relation to rTMS treatment parameters
Chi-square analysis showed no significant difference between those 
| D ISCUSS I ON
This exploratory observational study found that benzodiazepine use was associated with less improvement, whereas psychostimulant use was associated with greater improvement, after two weeks of rTMS treatment for depression. The relationships between medication use and clinical outcome were statistically significant even when controlling for baseline age, symptom severity, and sever- as measured by magnetic resonance spectroscopy (MRS) (Pehrson & Sanchez, 2015) , as well as emerging evidence that some effective treatments for depression are associated with enhanced or remediated GABA function. One prior rTMS investigation reported a trend-level negative association between change in medial prefrontal cortex GABA during a course of TMS and daily use of lorazepam (Dubin et al., 2016) . In rodent models, long-term administration of BDZ is associated with down-regulatory effects on GABA signaling, such as decreases in GABA A receptor subunit expression, including cortical alpha-1 mRNA (Uusi-Oukari & Korpi, 2010), decreased alpha-1 polypeptide (Chen, Huang, Zeng, Sieghart, & Tietz, 1999; Impagnatiello et al., 1996; Pesold et al., 1997) , and modified surface dynamics of GABA A Rs (Gouzer, Specht, Allain, Shinoe, & Triller, 2014) . These effects suggest that the concurrent, chronic use of BDZ medications could tend to mitigate the probable increases in cortical GABA signaling that appear with clinically effective rTMS.
Psychostimulants (in use by 31% of our sample) could enhance rTMS treatment outcomes through enhancement of plasticity as catecholaminergic agonists, most likely acting through adrenergic pathways. NE is a strong modulator of cortical plasticity, for example, in the hippocampus (Gu, 2002) . This finding also is consistent with the results of experiments testing the effects of noradrenergic agents on single-and paired-pulse TMS paradigms. Catecholamine transport inhibitors such as methylphenidate enhance the practice effect on single-pulse TMS-induced movement (Meintzschel & Ziemann, 2005) , and amphetamine enhances practice-related changes in cortical motor mapping (Tegenthoff, Cornelius, Pleger, Malin, & Schwenkreis, 2004) . Conversely, the selective alpha-1 adrenergic receptor antagonist prazosin abolishes the LTP-like motorevoked potential response in the paired-associate TMS paradigm (Korchounov & Ziemann, 2011) . These effects on plasticity are not mediated by changes in excitability per se, because the motor threshold is not altered by methylphenidate (Gilbert et al., 2006) , amphetamine (Boroojerdi, Battaglia, Muellbacher, & Cohen, 2001; Ziemann, Tergau, Bruns, Baudewig, & Paulus, 1997) , atomoxetine (Gilbert et al., 2006) , guanfacine (Boroojerdi et al., 2001) , or yohimbine (Plewnia, Bartels, Cohen, & Gerloff, 2001) . It is possible that these plasticity-modulating effects also are synergistic with rTMS, giving rise to relatively enhanced clinical outcomes for those patients concurrently taking noradrenergic agonist agents.
The present results could be consistent with an interaction between stimulation site/frequency and medication, in which Note. All models included baseline severity as a covariate. Change in symptom severity was assessed using the Inventory of Depressive Symptomatology Self Report (IDS-SR30) (Rush et al., 1996) . *p ≤ 0.05. 
| Limitations
This study is significant in that it offers the first systematic survey of relationships among the use of commonly prescribed medications 
| CON CLUS ION
The findings of this manuscript indicate important lines for future re- 
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